2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139994
    XN methyl pyrazole 2820169-36-4 98%
    XN methyl pyrazole (XP) is an orally active, blood-brain barrier permeable uncoupler/proton carrier. XN methyl pyrazole uncouples oxidative phosphorylation, depolarizes mitochondrial transmembrane potential, increases energy expenditure, spontaneous activity levels, and cortical inosine monophosphate levels. XN methyl pyrazole reduces plasma purine and energy metabolite levels, improves glucose tolerance, and decreases weight gain, while avoiding potential estrogenic side effects. XN methyl pyrazole can be used in studies related to diet-induced obesity and insulin resistance.
    XN methyl pyrazole
  • HY-141465
    3-Hydroxybutyryl-CoA 2871-66-1 98%
    3-Hydroxybutyryl-CoA is a metabolite which can be found in mouse or E.coli, et al. 3-Hydroxybutyryl-CoA has a 3-hydroxybutanoyl as the S-acyl component, and is an intermediate in the fermentation of butyric acid, and in the metabolism of lysine and tryptophan.
    3-Hydroxybutyryl-CoA
  • HY-141473
    Malonyl CoA tetralithium 116928-84-8
    Malonyl CoA (Malonyl coenzyme A) tetralithium is a substrate for fatty acid biosynthesis and an inhibitor of fatty acid oxidation. Malonyl CoA tetralithium is also a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1.
    Malonyl CoA tetralithium
  • HY-14147A
    (S)-Renzapride 98.06%
    (S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study.
    (S)-Renzapride
  • HY-141505
    Ovothiol A disulfide 73491-33-5 98%
    Ovothiol A disulfide is an inhibitor of light-triggered CF1 ATPase activity.
    Ovothiol A disulfide
  • HY-14153S
    Tegaserod-d11 1134188-56-9 98%
    Tegaserod-d11 is deuterated labeled Tegaserod (HY-14153). Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research.
    Tegaserod-d11
  • HY-141653
    MK-8666 tromethamine 2056254-98-7 98%
    MK-8666 (tromethamine) is a GPR40 agonist. MK-8666 (tromethamine) can be used in the research of type II diabetes.
    MK-8666 tromethamine
  • HY-141675
    Geranyl monophosphate 1609182-56-0 98%
    Geranyl monophosphate is an ester product.
    Geranyl monophosphate
  • HY-141728
    Bis(1-chloro-2-propyl) phosphate 789440-10-4 98%
    Bis(1-chloro-2-propyl) phosphate (BCIPP) is a metabolite of organophosphate flame retardants (OPFR) that may alter energy metabolism by influencing the levels of steroid hormones, such as cortisol and cortisone. Bis(1-chloro-2-propyl) phosphate holds potential for research on metabolism-related diseases caused by environmental exposure.
    Bis(1-chloro-2-propyl) phosphate
  • HY-141897
    3-Deoxy-D-arabino-heptulosonate 7-phosphate 2627-73-8 98%
    3-Deoxy-D-arabino-heptulosonate 7-phosphate is produced by the condensation of D-erythrose 4-phosphate with phosphoenolpyruvate (PEP), catalyzed by 3-deoxy-d-arabino-heptulosonate 7-phosphate (DAH 7-P) synthase (phe).
    3-Deoxy-D-arabino-heptulosonate 7-phosphate
  • HY-142088
    Beauverolide Ka 76265-42-4 98%
    Beauverolide Ka, a cyclotetradepsipeptide, is a metabolite of Beauveria bassiana fungus. Beauverolide Ka stimulates glucose uptake in cultured rat L6 myoblasts at 50 μM. Beauverolide Ka exhibits protecting effects on HEI-OC1 cells at 10 μM and shows dose-dependent activity in both L6 myoblasts and myotubes.
    Beauverolide Ka
  • HY-142521
    BLT2 probe 1 2893803-05-7 98%
    BLT2 probe 1 (compound 13) is a fluorescent probe based on the synthetic BLT2 agonist CAY10583. BLT2 is a promising target for diabetic wound healing and gastrointestinal lesions. BLT2 probe 1 is suitable to investigate the pharmacology of BLT2 receptor ligands in a variety of assay systems.
    BLT2 probe 1
  • HY-142643
    CETP-IN-4 1648889-70-6 98%
    CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor.
    CETP-IN-4
  • HY-142669
    Lp-PLA2-IN-4 2738877-91-1 98%
    Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38).
    Lp-PLA2-IN-4
  • HY-142670
    Lp-PLA2-IN-5 2738877-85-3 98%
    Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32).
    Lp-PLA2-IN-5
  • HY-142778
    Lp-PLA2-IN-10 2756855-45-3 98%
    Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4).
    Lp-PLA2-IN-10
  • HY-142779
    Lp-PLA2-IN-11 1620680-19-4 98%
    Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145).
    Lp-PLA2-IN-11
  • HY-142917
    THR-β agonist 4 2673409-25-9 98%
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72).
    THR-β agonist 4
  • HY-142985
    Oleyl Mesylate 35709-09-2 98%
    Oleyl Mesylate is a derivative of Oleyl Alcohol. Oleyl Alcohol has been incorporated into various formulations for drug delivery.
    Oleyl Mesylate
  • HY-142987
    Linoleyl methane sulfonate 51154-39-3 98%
    Linoleyl methane sulfonate is a selective lipid-based vehicle for use in drug delivery systems.
    Linoleyl methane sulfonate
Cat. No. Product Name / Synonyms Application Reactivity